Evidence map›Paper›PMID 37644107›Full record

ArticleScientific reports2023

Mechanism of salidroside in the treatment of endometrial cancer based on network pharmacology and molecular docking.

Panpan Yang, Yihong Chai, Min Wei, Yan Ge, Feixue Xu

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Deciphering the pharmacological mechanisms of salidroside in cervical cancer by combining network pharmacology, molecular docking, and in vitro studies.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Panpan YangDepartment of Obstetrics and Gynecology, First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China.
Yihong ChaiThe First Clinical Medical College of Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China.
Min WeiDepartment of Obstetrics and Gynecology, First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China.
Yan GeDepartment of Obstetrics and Gynecology, First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China.
Feixue XuDepartment of Obstetrics and Gynecology, First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China. xfx.sxq@163.com.
Lanzhou University · CNFirst Hospital of Lanzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Salidroside is a natural product of phenols, which has a wide scape of pharmacological effects, but its pharmacological effects and molecular mechanism on endometrial cancer are not clear. To systematically explore the pharmacological effects and molecular mechanisms of salidroside on endometrial cancer through the method of network pharmacology. The possible target genes of salidroside were obtained through different pharmacological databases and analysis platforms, and then the relevant target genes of endometrial cancer were obtained through the GeneCards website, and the target genes were uniformly converted into standardized gene names with Uniprot. The collected data were then processed to obtain common target genes and further analyzed through the String website to construct a protein-protein interaction (PPI) network, followed by gene ontology (GO) functional annotation and Kyoto Gene and Genome Encyclopedia (KEGG) pathway analysis. We further interpreted the molecular mechanism of salidroside for the treatment of endometrial cancer by constructing a "drug component-target gene-disease" network. Finally, we performed molecular docking to validate the binding conformation between salidroside and the candidate target genes. There were 175 target genes of salidroside after normalization, among which 113 target genes interacted with endometrial cancer. GO analysis indicated that the anti-endometrial cancer effect of salidroside may be strongly related to biological processes such as apoptosis and response to drug. KEGG analysis indicated that its mechanism may be related to pathway in cancer and PI3K-AKT signaling pathway. Molecular docking showed that salidroside had high affinity with five key genes. Based on the novel network pharmacology and molecular docking validation research methods, we have revealed for the first time the potential mechanism of salidroside in the therapy of endometrial cancer.

Indexed as

Endometrial NeoplasmsNetwork PharmacologyFemaleGlucosidesHumansMolecular Docking SimulationPhenolsPhosphatidylinositol 3-KinasesGlucosidesPhenolsPhosphatidylinositol 3-Kinasesrhodioloside

Identifiers

PMID37644107
PMCPMC10465614
OpenAlexW4386251656

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.